This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves - Scorecard - MDSpire

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward

  • May 26, 2026

  • 9 min

Share

Clinical Scorecard: This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

At a Glance

CategoryDetail
Condition
Key MechanismsAntibody-drug conjugates, microbiome co-therapy, anti-CD47 monoclonal antibodies
Target Population
Care Setting

Key Highlights

  • Sacituzumab tirumotecan met phase 3 endpoints in endometrial cancer.
  • MB097 showed positive phase 1b results in advanced melanoma.
  • Ligufalimab demonstrated a survival signal in phase 2 AML trial.
  • Regeneron's LAG-3 combination failed to meet phase 3 melanoma endpoint.
  • FDA approved first golimumab biosimilars.

Guideline-Based Recommendations

Diagnosis

  • Evaluate patients for advanced or recurrent cancer.

Management

  • Consider sacituzumab tirumotecan for endometrial cancer after prior therapies.
  • Use MB097 in combination with pembrolizumab for melanoma patients with primary resistance.

Monitoring & Follow-up

  • Monitor for adverse events in patients receiving microbiome therapy.

Risks

  • Assess risks of elevated viscosity and aggregation in high-concentration monoclonal antibodies.

Patient & Prescribing Data

Patients with advanced or recurrent cancer, including those ineligible for intensive chemotherapy.

Combination therapies are being explored for improved outcomes in various cancers.

Clinical Best Practices

  • Utilize pregnancy registries for postapproval safety studies.
  • Integrate protein engineering and real-time analytics in high-concentration mAb manufacturing.

Related Resources & Content

Original Source(s)

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

  • May 26, 2026

Related Content

When Insight Meets Urgency in Cell and Gene Therapy

Balancing deep biological insight with the realities of development is now central to progress in advanced medicine

New Mammography Screening Guidance: Clinical Considerations for Risk-Based Care

New guidance from the American College of Physicians (ACP) recommends biennial mammography screening for average-risk women ages 50 to 74.

  • by

  • May 26, 2026

  • 5 min
Beyond Nodule Detection: AI, Chest CT, and a Vision for Population Health

Lung cancer resulted in 1.8 million deaths globally in 2022 and remains the leading cause of cancer-related mortality worldwide. Low-dose CT screening has been shown to reduce lung cancer mortality, a...